CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives

 

Show simple item record

dc.contributor.author Boulton, Ian C en_ZA
dc.contributor.author Nwaka, Solomon en_ZA
dc.contributor.author Bathurst, Ian en_ZA
dc.contributor.author Lanzer, Michael en_ZA
dc.contributor.author Taramelli, Donatella en_ZA
dc.contributor.author Vial, Henri en_ZA
dc.contributor.author Doerig, Christian en_ZA
dc.contributor.author Chibale, Kelly en_ZA
dc.contributor.author Ward, Steve A en_ZA
dc.date.accessioned 2015-11-11T12:05:34Z
dc.date.available 2015-11-11T12:05:34Z
dc.date.issued 2010 en_ZA
dc.identifier.citation Boulton, I. C., Nwaka, S., Bathurst, I., Lanzer, M., Taramelli, D., Vial, H., ... & Ward, S. A. (2010). Commentary CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives. en_ZA
dc.identifier.uri http://hdl.handle.net/11427/14914
dc.identifier.uri http://dx.doi.org/10.1186/1475-2875-9-202
dc.description.abstract Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented. The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted.The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade. en_ZA
dc.language.iso eng en_ZA
dc.publisher BioMed Central Ltd en_ZA
dc.rights This is an Open Access article distributed under the terms of the Creative Commons Attribution License en_ZA
dc.rights.uri http://creativecommons.org/licenses/by/2.0 en_ZA
dc.source Malaria Journal en_ZA
dc.source.uri http://www.malariajournal.com/ en_ZA
dc.subject.other Drug Resistant Tuberculosis en_ZA
dc.subject.other Mass Drug Administration en_ZA
dc.subject.other Mass Drug Administration Campaign en_ZA
dc.subject.other Malaria Elimination en_ZA
dc.subject.other Anti-malarial Drug en_ZA
dc.subject.other Global Malaria Community en_ZA
dc.subject.other Vivax Malaria en_ZA
dc.subject.other Bed Net Distribution en_ZA
dc.subject.other Parasi en_ZA
dc.title CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives en_ZA
dc.type Journal Article en_ZA
dc.rights.holder 2010 Boulton et al; licensee BioMed Central Ltd. en_ZA
uct.type.publication Research en_ZA
uct.type.resource Article en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Science en_ZA
dc.publisher.department Department of Chemistry en_ZA
uct.type.filetype Text
uct.type.filetype Image


Files in this item

This item appears in the following Collection(s)

Show simple item record

This is an Open Access article distributed under the terms of the Creative Commons Attribution License Except where otherwise noted, this item's license is described as This is an Open Access article distributed under the terms of the Creative Commons Attribution License